[Clinical study on nephrology].
Imai
Enyu
E
Hamano
Takayuki
T
D000138:Acidosis / Q000188:drug therapy / Q000209:etiology; D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D001851:Bone Diseases, Metabolic / Q000188:drug therapy / Q000209:etiology; D002908:Chronic Disease; D000068256:Darbepoetin alfa; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D018753:Diet, Protein-Restricted; D004921:Erythropoietin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D007674:Kidney Diseases / Q000145:classification / Q000517:prevention & control; D008297:Male; D009398:Nephrology / Q000639:trends*; D012084:Renin-Angiotensin System
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D004921:Erythropoietin; D000068256:Darbepoetin alfa